Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension

American Journal of Hypertension

Volumn 11, Issue 2, 1998, Pages 235-239

  Jeng, Jing Ren ^a,b   Harn, Horng Jyh ^a   Yueh, Kuo Cheu ^a   Jeng, Chii Yuan ^a   Shieh, Shyh Ming ^b  

^a Chung Shan Hospital   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Angiotensin I converting enzyme; Gene polymorphism; Hypertension; Plasminogen activator inhibitor 1

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0031882098     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00476-7     Document Type: Article

References (35)

1. Cambien F, Poirier O, Lecerf L, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.
2. Ludwig E, Corneli PS, Anderson JL, et al: Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of cornary stenosis. Circulation 1995;91:2120-2124.
3. Evans AE, Poirier O, Kee F, et al: Polymorphism of the angiotensin-converting enzyme gene in subjects who die from coronary heart disease. Q J Med 1994;87:211-214.
4. Morris BJ, Zee RYL, Schrader AP: Different frequencies of angiotensin-converting enzyme genotype in older hypertensive individuals. J Clin Invest 1994;94:1085-1089.
5. Friedl W, Krempler F, Paulweber B, et al: A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Australian population. Atherosclerosis 1995;112:137-143.
6. Harrap SB, Davidson HR, Connor JM, et al: The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993;21:455-460.
7. Jeng JR, Harn HJ, Jeng CY, et al: Angiotensin I converting enzyme gene polymorphism in Chinese patients with hypertension. Am J Hypertens 1997;10:558-561.
8. Tiret L, Rigat B, Visvikis S, et al: Evidence from combined segregation and linkage analysis that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;1:197-205.
9. Costerousse O, Allegrini J, Lopez M, et al: Angiotensin I-converting enzyme in human peripheral mononuclear cells: main expression in T-lymphocytes under the influence of a genetic polymorphism. Biochem J 1993; 290:33-40.
10. Ridker PM, Gaboury CL, Conlin PR, et al: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic system. Circulation 1993;87:1969-1973.
11. Smith D, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985;66:835-839.
12. Panahloo A, Andrès C, Mohamed-Ali V, et al: The insertion allele of the ACE gene I/D polymorphism: a candidate gene for insulin resistance? Circulation 1995; 92:3390-3393.
13. Landin K, Tengborn L, Smith U: Elevated fibrinogen and plasminogen activator inhibitor-1 (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-278.
14. Jeng JR, Sheu WHH, Jeng CY, et al: Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996;9:484-490.
15. Wright RA, Flapan AD, Alberti KGMM, et al: Effect of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol 1994;24:67-73.
16. Harn HJ, Chang CY, Ho LI, et al: Evidence that polymorphism of the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in the Chinese population. Biochem Mol Biol Intern 1995; 35:1175-1181.
17. Kluft C, Jie AFH, Rijken DC, et al: Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fasting acting inhibitor (PAI-1). Thromb Haemost 1989;59:329-332.
18. Bergsdorf N, Nilsson T, Wallén P: An enzyme-linked immunosorbent assay for tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 1983;50:740-744.
19. Rånby M, Bergsdorf N, Nilsson T, et al: Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986;32:2160-2165.
20. Declerck PJ, Alessi M-C, Verstreken M, et al: Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988;71:220-225.
21. Chmielewska J, Rånby M, Wiman B: Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983;31:427-436.
22. Van Leeuwen RTJ, Koll A, Andreotti F, et al: Angiotensin II increases plasminogen activator inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rate aortic smooth muscle cells. Circulation 1994;90:362-368.
23. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells. J Clin Invest 1995;95:995-1001.
24. Hamdan AD, Quist WC, Gagne JB, et al: Angiotensin-converting enzyme inhibitor suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996;93:1073-1078.
25. Lachurié ML, Azizi M, Guyebe TT, et al: Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995;91:2933-2942.
26. Hamsten A, Wiman B, deFaire U, et al: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
27. Huber K, Jorg M, Probst P, et al: A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992;67:209-213.
28. Hamsten A, Walldins G, Szamosi A, et al: Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;ii:3-9.
29. Vague PH, Juhan-Vague I, Aillaud MF, et al: Correlations between blood fibrinolytic activity, plasminogen activator inhibitor levels, plasma insulin and relative body weight in normal and obese subjects. Metab Clin Exp 1986;35:250-253.
30. Juhan-Vague I, Vague PH, Alessi MC, et al: Relationship between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor-1. Diabete Metab 1987;13:331-336.
31. Juhan-Vague I, Roul C, Alessi MC, et al: Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 1989;61:370-373.
32. Mehta J, Mehta P, Lawson D, et al: Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263-268.
33. Eriksson P, Kallin B, va't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-1855.
34. Ye S, Green FR, Scarabin PY, et al: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837-841.
35. Panahloo A, Mohamed-Ali V, Lane A, et al: Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995;44:37-42.